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Background: In congenital diaphragmatic hernia (CDH), pulmonary hypertension increases right
ventricle (RV) afterload, which could impair heart function and contribute to poor outcome for most
affected infants. Nevertheless, the real significance of vascular pulmonary alterations in perinatal
hemodynamics is largely unknown. It is defined that ventricular pressure overload induces increased
myocardium gene expression of B-type natriuretic peptide (BNP) and components of the renin-
angiotensinogen and endothelin (ET)–1 systems. Our aim was to evaluate perinatal myocardium
expression of these genes associated with ventricular pressure overload in a nitrofen-induced CDH
rat model.
Methods: In the nitrofen-induced CDH rat model, fetuses from dated pregnant Sprague-Dawley rats at
15.5, 17.5, 19.5 and 21.5 days postcoitum as well as newborn pups were assigned to 3 experimental
groups: control, nitrofen (exposed to nitrofen, without CDH), and CDH (exposed to nitrofen, with
CDH). Myocardial samples collected from the RV and left ventricle (LV) were processed for
quantification of messenger RNA (mRNA) of BNP, angiotensinogen, and ET-1.
Results: The perinatal expression of BNP, angiotensinogen, and ET-1 mRNA in the RV and LV of the
control group revealed daily changes. During gestation, the expression of BNP and angiotensinogen
mRNA underwent significant oscillation compared with control in both nitrofen-exposed fetuses,
although we cannot identify significant differences between the nitrofen and CDH groups. After birth,
we found a significant increasing expression of all studied genes only in the RV of CDH pups.
Conclusions: Perinatal myocardial quantification of BNP, angiotensinogen, and ET-1 mRNA levels
suggests that both nitrofen-exposed and control pups revealed prenatal variations of expression of the
studied genes. Moreover, CDH is associated with significant molecular alterations only in the RV
after birth.
© 2008 Elsevier Inc. All rights reserved.⁎ Corresponding author. Escola de Ciências da Saúde, Universidade do
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oi:10.1016/j.jpedsurg.2007.08.044Despite improvements in perinatal care, the mortality of
fetuses and newborns with congenital diaphragmatic hernia
(CDH) remains exceedingly high [1]. This mortality seems to
be related with severe pulmonary hypoplasia and pulmonary
628 M.J. Baptista et al.hypertension (PH) [2]. Several authors suggested that, even
in the absence of congenital heart disease, these infants could
experience of some degree of cardiac underdevelopment
[3,4]. In previous studies, we demonstrated in the experi-
mental rat model of CDH the absence of left ventricle (LV)
hypoplasia [5,6] or myocardium immaturity [7] in CDH
fetuses. Nevertheless, the real significance of increased right
ventricle (RV) afterload, because of neonatal PH, in heart
function is still unknown.
Another question that still persists in CDH is the true
significance of PH in fetal hemodynamics and its
consequences for the fetal heart. In infants with CDH,
pulmonary vascular modifications occur from early stages
of prenatal development [8] and assume obvious signifi-
cance after birth. Nevertheless, their meaning in fetal heart
function is uncertain. Because fetal heart function is not
easily assessed by ultrasonography, the evaluation of
markers of ventricular overload in an experimental model
of CDH might provide an appropriate alternative. Several
biochemical and genetic markers have been suggested to
evaluate ventricular load and function, both in animal
models and humans, such as B-type natriuretic peptide
(BNP), components of the renin-angiotensin system, and
endothelin (ET)–1[9].
B-type natriuretic peptide is a hormone of predominantly
ventricular origin produced and released in response to
increased ventricular wall stress [10,11]. In recent years, it
has emerged as a very sensitive biochemical marker for
ventricular dysfunction in heart failure as well as in PH, and
its plasmatic level could be used to guide the response to
therapy and to predict prognosis [12,13]. During normal fetal
rat development, a very intense expression of BNP in the
heart from 9.5 days postcoitum (dpc) was demonstrated, with
major peaks of expression in stages that coincide with
landmarks in heart development [14].
The components of the renin-angiotensin system and their
roles in adult cardiac hypertrophy have been well documen-
ted [15,16]. In adult hearts, the increased hemodynamic load
results in increased levels of angiotensin II that stimulates
significant hypertrophy and remodeling of cardiac structure.
Recent evidence from in vivo studies indicates that
angiotensin II also acts as a growth factor and has a potential
role in embryonic, fetal, and neonatal development of the
heart [17-19]. In addition, the AT1 and AT2 angiotensin II
receptor subtypes are present in the heart and are
developmentally regulated [20].
Endothelin 1 is a potent vasoconstrictor peptide derived
from endothelial cells that is also produced by cardiac
myocytes [21]. Endothelin 1 induces myocardial cell
hypertrophy and has potent positive inotropic and chrono-
tropic effects on isolated heart muscle. These actions are
mediated by the receptors for ET-1 (ETA and ETB receptors)
on the cardiac myocytes [22]. The production of ET-1 in the
heart is increased in pressure overload conditions, such as PH
[23]. Several studies demonstrated that ET system has an
important role in the developing heart, contributing to theformation of anatomical structures such as heart outflow tract
and great vessels [24].
Interestingly, it was suggested in several previous studies
that natriuretic peptides, angiotensin II, and ET-1 could play
a significant role in the PH associated with CDH [25-29].
Moreover, in the rat model of CDH, several authors reported
significant modifications in heart expression of components
from all these systems. Nevertheless, none of these studies
assessed the messenger RNA (mRNA) expression of all
these genes in both ventricles throughout gestation [30-32].
The aim of the current study was to evaluate, in the
nitrofen-induced CDH rat model, LV and RV mRNA
expression of BNP, angiotensinogen, and ET-1, genes
previously defined as ventricular overload markers, in an
attempt to evaluate the significance of PH in myocardium
molecular adaptation during fetal development and transition
after birth.1. Materials and methods
The protocols used in this investigation were approved by
the Institutional Animal Care and Use Committee and
conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
Bethesda, MD, (publication no. 85-23, revised 1996).
1.1. Animal model
Pregnancy was obtained in 22 female Sprague-Dawley
rats (225 g; Criffa, SA, Barcelona, Spain) after controlled
overnight mating, and the finding of vaginal plug was
counted as day 0. At 9.5 dpc, pregnant rats were exposed to
100 mg of nitrofen (2,4-dichlorophenyl-p-nitrophenylether)
dissolved in 1 mL of olive oil administered by gavage or to
an equal volume of olive oil alone [33]. Randomly, fetuses,
treated with nitrofen or olive oil, were harvested by cesarean
section at 15.5, 17.5, 19.5, and 21.5 dpc (term gestation,
22 days), weighed on a precision balance (SBC 21; Scaltec
Instruments, Heeligeesdadt, Germany), and killed by
decapitation. To evaluate newborn rats, the gestation was
continued in some pregnant rats until 22 dpc, and rats were
allowed to deliver spontaneously. Newborns rats were
harvested immediately after death or electively killed, by
decapitation, at 6 hours after delivery. In this regard, it might
be emphasized that all CDH pups died before our set point.
After weighing pups, laparotomy was performed under
binocular surgical microscopy (Wild M651.MS-D; Leica,
Herbrugg, Switzerland) to inspect the diaphragm. Hearts
were excised en bloc through median sternotomy. Myocar-
dial samples were harvested from LV and RV free wall and
snap-frozen at −80° for further molecular studies. Fetuses
were assigned to the following 3 experimental groups:
(i) control group—fetuses or pups exposed to olive oil alone,
without CDH; (ii) nitrofen group—fetuses or pups exposed
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pups exposed to nitrofen with CDH. Fetuses and pups with
structural cardiac defects were excluded. Because it was not
feasible to accurately identify a diaphragmatic defect at 15.5
dpc, only 2 groups were defined: control and nitrofen
(exposed to nitrofen with or without CDH).
1.2. Molecular studies
1.2.1. Ribonucleic acid extraction and
reverse transcription
Total mRNA from LV and RV samples of 150 fetuses
(n = 10 each for control, nitrofen, and CDH, in each studied
time-point: 15.5 dpc, 17.5 dpc, 19.5 dpc, 21.5 dpc, and
newborn) was extracted using the RNeasy Mini Kit
Protect (74712; Qiagen, Hilden, Germany). Quantification
of total mRNA was done by spectrophotometry (BioPhot-
ometer, Eppendorf, Germany), and the A260/A280 ratio
was used to test protein and deoxyribonucleic contamina-
tion of the extracted product.
Reverse transcription was performed as previously
described by Santos et al [34].
1.2.2. Quantitative polymerase chain reaction
Quantitative real-time polymerase chain reaction was
performed as previously described by Santos et al [34].
Primer design was based on the available sequences in
GenBank (NCBI-NLM-PubMed-Gene). All the primers are
intron spanning (Table 1). For all the primer sets, standard
amplification curves (ST curves) were made with randomly
selected complementary DNA samples, setting r = 0.99. The
samples gene's expression was normalized for β-actin.
1.3. Statistical analysis
Results were presented as mean ± SEM. Statistical
analysis was performed using the SigmaStat 3.5 software
(London, England). The different data sets of control,
nitrofen, and CDH groups failed in the Kolmogorov-
Smirnov test for normality. Therefore, statistical analysis
was performed by the 1-way analysis of variance on ranks
and the Dunn test for posttest analysis. Statistical signifi-
cance was set at P b .05.Table 1 Primers used for quantitative polymerase chain reaction
Gene Accession no. Primer set
BNP NM_031545 5′-GCA GAA GCT
5′-GCT GTC TTG A
Angiotensinogen NM_134432 5′-GGATAAGTCCA
5′-CAGACACCCCT
ET-1 NM_012548 5′-CAGAAACAGC
5′-GGAGGAGCAG
β-actin NM_031144 5′-GAT TTG GCA C
5′-ACT TTG GTC A2. Results
The mRNA levels of BNP, angiotensinogen, and ET-1
(through gestation, in the RV and LV, in the control, nitrofen,
and CDH groups) are presented in Figs. 1–3, respectively.
The BNP mRNA expression in the RV demonstrated in
control group a significant decrease of around 19.5 dpc,
followed by a peak increase at 21.5 dpc. After birth, its levels
are similar to earlier studied stages of heart development. In
comparison with the control group, we found significant
differences both in nitrofen and CDH groups, characterized by
a mirror-image pattern of expression, with inverse peak
increase at 19.5 dpc and a subsequent decrease at 21.5 dpc.
After birth, the BNP mRNA expression in RV was similar in
the nitrofen and control groups, but in the CDH group, we
found a significant increase in its expression (5.5-fold) (Fig. 1).
The BNP mRNA expression in LV revealed a similar
expression pattern in all study groups during fetal develop-
ment. The control group had a significant decrease of around
19.5 dpc followed by an increase at 21.5 dpc, although its
magnitude was not as evident as occurred in the RV.
Regarding the nitrofen and CDH groups, we also found a
mirror-image pattern of expression. Nevertheless, after birth,
the levels of BNP mRNAwere similar to prior stages of heart
development in the 3 groups (Fig. 1).
Concerning the expression of angiotensinogen mRNA in
the RV, we observed a slight increase from 17.5 dpc that
peaked at 19.5 dpc, followed by a decrease to basal levels at
21.5 dpc. After birth, its levels remained constant. In the
nitrofen and CDH groups, there was no significant variation
in angiotensinogen mRNA expression through gestation. At
birth, a significant rise occurred in the CDH group, compared
with the control and nitrofen groups (Fig. 2).
Similar to the expression of BNP, in the control group, we
found an LV angiotensinogen mRNA expression pattern
similar to RV. Its expression rose from 17.5 dpc, peaked at
19.5 dpc, then slowly decreased until birth. Regarding the
nitrofen and CDH groups, angiotensinogen mRNA levels in
LV did not vary during gestation and after birth (Fig. 2).
In the control group, ET-1 mRNA level in RV showed a
significant peak of expression at 19.5 dpc, followed by a
constant level of expression that persisted even after birth.
During fetal development, both the nitrofen and CDH groupsProduct size (base pair)
GCT GGA G-3′ 118
GA CCT AAG GA-3′
GAGAGCGAG-3′ 129
GCTACAGTC-3′
TGTCTTGGGA-3′ 116
GAGCAACG-3′
CA CAC TTT CTA CA-3′ 114
TC TTT TCA CGG TTG G-3′
ig. 2 Expression of angiotensinogen mRNA from 15.5 dpc to
hours of postnatal life in control, nitrofen, and CDH fetuses, both
RV (upper) and LV (bottom). *P b .05 vs control group; ξP b .05
6 dpc.
Fig. 1 Expression of BNP mRNA from 15.5 dpc to 6 hours of
postnatal life in control, nitrofen, andCDH fetuses, both inRV (upper)
and LV (bottom). *P b .05 vs control group; ξP b .05 vs 16 dpc.
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significant difference from control. However, after birth,
whereas in the nitrofen group, we did not found any
difference from the control group, the CDH group had a
significant increase in ET-1 mRNA expression (Fig. 3).
Finally, the LV the expression of ET-1 mRNA showed a
peak at 21.5 dpc and returned to baseline levels after birth. In
the nitrofen and CDH groups, we found the same pattern of
expression of the gene, without any difference compared
with the control group (Fig. 3).
To evaluate the relative expression changes of mRNA of
studied genes in the LV and RV after birth, we used the RV-
to-LV mRNA ratio (Fig. 4). In the control group, mRNA of
the 3 genes had similar relative expression in both ventricles.
On the other hand, in the CDH group, we found a very
significant increase in the RV-to-LV ratio expression patterns
of BNP, angiotensinogen, and ET-1.
3. Discussion
In this study, we determined the cardiac expression of
BNP, angiotensinogen, and ET-1 mRNA during perinataldevelopment in normal and nitrofen-exposed rats. Cardiac
expression of these genes showed temporal changes,
suggesting a closely regulated developmental expression.
Our results also showed late fetal cardiovascular disturbances
in nitrofen-exposed fetuses. Moreover, it clearly illustrates
that CDH pups, in early postnatal adaptation, experience
severe RV molecular adaptation to pressure overload.
In our day, CDH remains a challenge in perinatology.
The most severely affected babies have an extremely high
mortality rate despite aggressive treatment. Persistent
hypoxia because of pulmonary hypoplasia and hypertension
is considered by several authors as the main problem in
CDH. Nevertheless, centers without extracorporeal mem-
brane oxygenation did not significantly improve the
outcome using techniques targeted to lung-dependent
oxygenation, such as high-frequency ventilation or pulmon-
ary vasodilator therapy. Although the real significance of PH
is not completely defined in infants with CDH, it is well
known that severe PH is associated with increased mortalityF
6
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ig. 4 Right ventricle–to–LV mRNA ratio of BNP, angiotensi-
ogen, and ET-1 in control and CDH groups at 6 hours after birth.
P b .05 vs control group.
Fig. 3 Expression of ET-1 mRNA from 15.5 dpc to 6 hours of
postnatal life in control, nitrofen, and CDH fetuses, both in RV
(upper) and LV (bottom). *P b .05 vs control group; ξP b .05 vs
16 dpc.
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as well as hampers myocardial performance, with addi-
tional compromise of pulmonary blood flow and tissue
oxygenation [36].
From fetal to adult life, cardiopulmonary interaction plays
a significant role in physiologic hemodynamics. Pathologic
conditions affecting the lung or the heart could hamper this
equilibrium. Although the pulmonary consequences of
cardiac disease are well recognized, the influences of
pulmonary changes on cardiac function are less well
appreciated, particularly in fetuses. In late fetal life, several
physiologic hemodynamic changes occur, such as initiation
of ductus arteriosus closure and pulmonary vasodilatation, as
well as increase in RV output to the pulmonary artery [37].
These modifications are promoted by many paracrine
factors, among which systems such as natriuretic peptides,
angiotensin, and ET-1 are supposed to play a role in different
stages of heart development. Although significant alterations
in these systems are well documented in pressure and volume
cardiac overload in adults, the exact expression pattern of
these genes in relation to fetal cardiac load was not
previously defined. In our study, we demonstrated adistinctive cardiac expression pattern of these genes during
normal perinatal fetal rat development, presumably related to
hemodynamic variations.
Endothelin 1 mRNA expression is different in the LVand
RV, probably because of different loads in the LV and RV.
This gene has a peak expression at 19.5 dpc in the RV,
whereas in the LV, this occurs at 21.5 dpc. On the other hand,
angiotensinogen and BNP have a very similar expression
pattern in the RV and LV but a mirror expression compared
with each other. We established that, in both ventricles, when
BNP increases, angiotensinogen decreases. The opposed
effect of natriuretic peptides and angiotensin in myocardium
as well as in vessels is well known. Generally, BNP has
potent inhibitory effects on the renin-angiotensin-aldoster-
one system [38], and in heart failure, activation of the renin-
angiotensin-aldosterone system is suppressed by BNP [39].
These systems might form an important regulatory complex
of fetal vascular physiology and development. Hypotheti-
cally, dysregulation of these delicate control mechanisms
could interfere with the cardiopulmonary hemodynamics and
lead to disease.
Pulmonary vascular abnormalities in CDH have been well
described from early stages of lung development. They
consist of fewer pulmonary arteries per unit lung volume and
peripheral muscularization of small arteries with medial and
adventitial thickening [8]. Although the underlying mechan-
isms are not completely understood, these anomalies may
cause abnormal vascular reactivity, and CDH lungs may
become unable to adapt normally at birth [40]. The
importance of abnormal vascular development as a determi-
nant of survival in CDH has just recently been appreciated.
Nonetheless, we are far from understanding the specific
interplay of the factors regulating vascular tone in CDH as
well as the significance of those anomalies during fetal heart
and lung development.
In our work, we intended to define the fetal and neonatal
expression pattern of 3 genes related to ventricular pressureF
n
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632 M.J. Baptista et al.load in the nitrofen rat model of CDH. We demonstrated that
during late fetal life, the nitrofen-exposed fetuses had
significant variations in heart expression of mRNA BNP
and angiotensinogen, evocative of cardiovascular distur-
bances. Remarkably, the mirror expression pattern of these
2 genes observed in control rat fetuses is preserved in
nitrofen-exposed fetuses. Nevertheless, there are no altera-
tions in ET-1 mRNA cardiac expression, and the variation
reported in angiotensinogen and BNP genes occurred both in
CDH and non-CDH nitrofen–exposed fetuses. These results
suggest that the abnormalities observed are probably
consequence of nitrofen action and not related to a
hypothetical pulmonary vascular remodeling. We believe
that, as occurs in several congenital malformations, PH in
CDH is balanced during fetal life and should not have
hemodynamic consequences or induce cardiac adaptation. In
fact, pulmonary vascular remodeling, when present, should
not cause elevated RV pressures in the fetus given the
presence of the ductus arteriosus.
In infants with CDH, intrauterine pulmonary hypoplasia
and vascular remodeling may cause failure of pulmonary
vascular resistance to fall at birth. This event implies an
increased pressure overload to RV, with additional wall and
endothelium stress, responsible for the initiation of cardiac
adaptation. Several studies suggest that in PH, the LV
experiences both systolic and diastolic function adaptation
because of bulging of the ventricular septum and diminished
RV output [41]. In our study, the increased levels of all
studied cardiac pressure overload markers in the RVof CDH
pups after birth may indicate increased pulmonary vascular
resistance in the CDH group. This response is specific for
RV, and in this model, we did not demonstrate any LV
molecular adaptation to PH.
In conclusion, perinatal myocardial quantification of
BNP, ET-1, and angiotensinogen mRNA demonstrated that
CDH is associated with significant molecular adaptation only
in RV after birth. In fact, although nitrofen induced a
hemodynamic imbalance in the expression of these genes,
the major and novel observation from our work is the
absence of cardiac impact of PH during late fetal life.References
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